8.2 Major Drug Classifications & Therapeutic Actions

8.2 Major Drug Classifications & Therapeutic Actions

Medical assistants must possess a comprehensive understanding of major pharmaceutical classifications to assist providers effectively, accurately review patient medication lists during rooming, recognize potential adverse reactions, and deliver vital patient education. Identifying drug classes by their characteristic prefixes, root words, and suffixes provides a reliable framework for understanding therapeutic mechanisms, side effect profiles, and clinical contraindications.

---

1. Cardiovascular & Hematologic Medications

Cardiovascular pharmacotherapy addresses hypertension, coronary artery disease, heart failure, cardiac dysrhythmias, thromboembolism, and hyperlipidemia.

+---------------------------------------------------------------------------------------------------+
|                             CARDIOVASCULAR PHARMACOTHERAPY AT A GLANCE                            |
+---------------------------------------------------------------------------------------------------+
| ACE Inhibitors     | Suffix: -pril (lisinopril, enalapril); blocks Angiotensin II; dry cough risk.|
| ARBs               | Suffix: -sartan (losartan, valsartan); blocks AT1 receptors; no cough.       |
| Beta-Blockers      | Suffix: -lol (metoprolol, atenolol); lowers HR & BP; bronchospasm risk.      |
| Calcium Blockers   | Suffix: -dipine (amlodipine, nifedipine); relaxes vascular smooth muscle.    |
| Diuretics          | Thiazide (HCTZ), Loop (furosemide/Lasix), K-Sparing (spironolactone).        |
| Antianginal        | Sublingual Nitroglycerin (1 tab q5min x 3 doses max; amber glass bottle).   |
| Anticoagulants     | Warfarin (PT/INR; Antidote: Vit K); Heparin (Antidote: Protamine Sulfate).    |
| Statins            | Suffix: -statin (atorvastatin); lowers LDL; monitor liver & rhabdomyolysis.  |
+---------------------------------------------------------------------------------------------------+

Antihypertensive Drug Classes

1. Angiotensin-Converting Enzyme (ACE) Inhibitors:
   • Identifying Suffix: -pril (e.g., lisinopril, enalapril, captopril, ramipril).
   • Mechanism of Action: Inhibit ACE from converting Angiotensin I to Angiotensin II (a potent vasoconstrictor) and prevent the breakdown of bradykinin, leading to systemic vasodilation and decreased aldosterone secretion (promoting renal sodium and water excretion while retaining potassium).
   • Key Side Effects & Clinical Precautions: Chronic dry, hacking non-productive cough (caused by bradykinin accumulation; seen in up to $15-20%$ of patients); risk of life-threatening angioedema (rapid swelling of lips, tongue, pharynx, and face requiring immediate emergency airway intervention); hyperkalemia (elevated serum potassium); and orthostatic hypotension. Teratogenic: contraindicated in pregnancy.
2. Angiotensin II Receptor Blockers (ARBs):
   • Identifying Suffix: -sartan (e.g., losartan, valsartan, irbesartan, olmesartan).
   • Mechanism of Action: Selectively block Angiotensin II from binding to the $AT_1$ receptor in vascular smooth muscle and the adrenal cortex, producing vasodilation and reducing aldosterone.
   • Clinical Advantage: Does not inhibit bradykinin breakdown, making ARBs the primary clinical alternative for patients who develop an intolerable ACE inhibitor dry cough.
3. Beta-Adrenergic Blockers (Beta-Blockers):
   • Identifying Suffix: -lol (e.g., metoprolol, atenolol, propranolol, carvedilol, labetalol).
   • Mechanism of Action: Block beta-1 receptors on cardiac tissue, decreasing heart rate (negative chronotropy), myocardial contractility (negative inotropy), and cardiac output; also decrease renin release from kidneys.
   • Clinical Safety Rules:
     • Always check the patient's resting apical pulse and blood pressure before administration; hold medication and alert provider if heart rate is $<60\text{ bpm}$ or systolic BP is $<90-100\text{ mmHg}$.
     • Non-Selective Beta-Blockers (e.g., propranolol, carvedilol): Block both beta-1 and beta-2 receptors. Beta-2 blockade induces bronchospasm and bronchoconstriction, making non-selective agents strictly contraindicated in patients with asthma and severe COPD.
     • Diabetic Warning: Beta-blockers mask early sympathetic symptoms of hypoglycemia (tachycardia, tremors, palpitations), leaving diaphoresis (sweating) as the primary remaining warning sign.
4. Calcium Channel Blockers (CCBs):
   • Identifying Suffix: -dipine for dihydropyridines (e.g., amlodipine, nifedipine); non-dihydropyridines include diltiazem and verapamil.
   • Mechanism of Action: Inhibit the influx of calcium ions into cardiac and vascular smooth muscle cells during membrane depolarization, relaxing coronary and peripheral arterioles, reducing systemic vascular resistance, and slowing AV nodal conduction.
   • Adverse Effects: Peripheral lower-extremity edema (swollen ankles), bradycardia, reflex tachycardia (dihydropyridines), dizziness, flushing, and severe constipation (especially verapamil).
5. Diuretics:
   • Thiazide Diuretics (e.g., hydrochlorothiazide [HCTZ], chlorthalidone): Inhibit sodium and chloride reabsorption in the distal convoluted tubule; first-line therapy for uncomplicated hypertension. Adverse Effects: Hypokalemia (low potassium), hyponatremia, hyperuricemia (triggering acute gout attacks), and hyperglycemia.
   • Loop Diuretics (e.g., furosemide [Lasix], bumetanide, torsemide): Potent diuretics inhibiting the $\text{Na}^+/\text{K}^+/2\text{Cl}^-$ symporter in the thick ascending limb of the loop of Henle; used for acute pulmonary edema, congestive heart failure, and renal insufficiency. Adverse Effects: Severe hypokalemia, dehydration, hypotension, and ototoxicity (tinnitus and hearing loss with rapid IV boluses).
   • Potassium-Sparing Diuretics (e.g., spironolactone [Aldactone], triamterene): Compete with aldosterone in the distal tubule to excrete sodium and water while retaining potassium. Adverse Effects: Hyperkalemia (potassium $>5.0\text{ mEq/L}$; risk of fatal cardiac dysrhythmias); avoid potassium supplements or salt substitutes containing potassium chloride; spironolactone may cause gynecomastia in males.

Antianginal Therapy: Nitroglycerin Protocol

• Therapeutic Action: A potent organic nitrate that converts to nitric oxide in vascular smooth muscle, producing extensive venous and coronary vasodilation, dramatically reducing cardiac preload, myocardial oxygen demand, and coronary spasm.
• Acute Sublingual Protocol for Angina Pectoris:
  1. At the first onset of acute substernal chest pain, the patient must sit down immediately (to prevent orthostatic hypotension and syncope) and place 1 sublingual (SL) tablet (0.4 mg) or 1 SL spray under the tongue; allow it to dissolve completely without swallowing or chewing.
  2. If chest pain persists after 5 minutes, the patient or caregiver should call 911 (emergency medical services) immediately, and take a second SL tablet.
  3. If chest pain continues after another 5 minutes, a third SL tablet may be taken (maximum of 3 tablets in 15 minutes).
• Storage & Stability Guidelines: Nitroglycerin is extremely unstable and decomposes upon exposure to heat, light, air, and moisture. It must be kept in its original, tightly sealed amber glass container with the metal cap screwed tight. Never transfer to plastic pill minders. Discard and replace opened bottles after 6 months.
• Common Side Effects: Throbbing headache, facial flushing, dizziness, and marked hypotension. Strictly contraindicated with PDE-5 inhibitors (e.g., sildenafil / Viagra, tadalafil / Cialis) within 24–48 hours due to catastrophic, refractory fatal hypotension.

Anticoagulants, Antiplatelets & Critical Antidotes

+---------------------------------------------------------------------------------------------------+
|                             ANTICOAGULATION MONITORING & REVERSAL AGENTS                          |
+---------------------------------------------------------------------------------------------------+
| Warfarin (Coumadin) | Monitored via PT / INR (Target: 2.0 - 3.0)     | Antidote: VITAMIN K         |
| Heparin (UFH)       | Monitored via aPTT                            | Antidote: PROTAMINE SULFATE |
| DOACs (Eliquis)     | Direct Factor Xa Inhibitors (apixaban)        | Antidote: Andexanet Alfa    |
| Antiplatelets       | Aspirin, Clopidogrel (Plavix) - blocks agg.   | Platelet Transfusions       |
+---------------------------------------------------------------------------------------------------+

• Warfarin (Coumadin): Vitamin K antagonist inhibiting hepatic synthesis of clotting factors II, VII, IX, and X. Monitored clinically using Prothrombin Time (PT) and International Normalized Ratio (INR) (therapeutic target INR is typically 2.0 to 3.0 for atrial fibrillation/DVT, or 2.5 to 3.5 for mechanical heart valves). Antidote / Reversal Agent: Vitamin K (phytonadione); for acute hemorrhage, fresh frozen plasma (FFP) or 4-factor prothrombin complex concentrate (4F-PCC).
• Unfractionated Heparin: Enhances antithrombin III activity, inactivating thrombin and Factor Xa. Monitored via activated Partial Thromboplastin Time (aPTT). Antidote / Reversal Agent: Protamine Sulfate ($1\text{ mg}$ neutralizes approx. 100 units of heparin).
• Direct Oral Anticoagulants (DOACs): Direct Factor Xa inhibitors (apixaban [Eliquis], rivaroxaban [Xarelto]) and direct thrombin inhibitors (dabigatran [Pradaxa]). Do not require routine coagulation blood monitoring.
• Antiplatelet Agents: Inhibit platelet aggregation and thrombus formation. Includes aspirin (irreversible COX-1 inhibitor) and clopidogrel (Plavix) (ADP / $P2Y_{12}$ receptor blocker). Used for stroke and myocardial infarction prophylaxis.

Antihyperlipidemic Agents: Statins

• Identifying Suffix: -statin (e.g., atorvastatin [Lipitor], simvastatin [Zocor], rosuvastatin [Crestor]).
• Mechanism of Action: Inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, significantly lowering circulating Low-Density Lipoprotein (LDL) and triglycerides while elevating High-Density Lipoprotein (HDL).
• Safety Monitoring & Adverse Effects:
  • Hepatotoxicity: Baseline and periodic monitoring of liver function tests (AST, ALT) is required.
  • Myopathy & Rhabdomyolysis: Patients must be educated to report unexplained muscle pain, tenderness, weakness, or dark "tea-colored" urine immediately (indicating myoglobinuria and acute renal failure). Statins are contraindicated in active liver disease and pregnancy.

---

2. Endocrine & Metabolic Agents

Antidiabetic Pharmacotherapy: Insulin Regimens

Insulin facilitates cellular uptake of glucose for energy and glycogen storage. In Type 1 Diabetes Mellitus, exogenous insulin is mandatory for life; in Type 2 Diabetes, it is utilized when oral agents fail to achieve glycemic targets ($\text{HbA1c} < 7.0%$).

+---------------------------------------------------------------------------------------------------+
|                                 INSULIN PHARMACOKINETIC PROFILES                                  |
+---------------------------------------------------------------------------------------------------+
| CATEGORY         | GENERIC NAME (BRAND)       | ONSET         | PEAK          | DURATION          |
+------------------+----------------------------+---------------+---------------+-------------------+
| Rapid-Acting     | Lispro (Humalog), Aspart   | 10 - 15 min   | 30 - 90 min   | 3 - 5 hours       |
| Short-Acting     | Regular Insulin (Humulin R)| 30 - 60 min   | 2 - 4 hours   | 5 - 8 hours       |
| Intermediate     | NPH Insulin (Humulin N)    | 1 - 2 hours   | 4 - 12 hours  | 18 - 24 hours     |
| Long-Acting      | Glargine (Lantus), Detemir | 1 - 2 hours   | NO PEAK (Flat)| 24 hours          |
+---------------------------------------------------------------------------------------------------+

• Rapid-Acting Insulin (Lispro / Aspart / Glulisine): Administered immediately before meals ($5-15\text{ minutes}$) to control postprandial glucose surges. Food must be in front of the patient before injection.
• Short-Acting Insulin (Regular): The only insulin formulation that can be administered intravenously (IV) in emergency management of Diabetic Ketoacidosis (DKA).
• Intermediate-Acting Insulin (NPH): Cloudy suspension; must be gently rolled between palms to resuspend (never shaken violently). When mixing Regular and NPH in a single syringe, always draw "Clear before Cloudy" (Regular first, then NPH) to prevent contaminating the regular vial.
• Long-Acting Insulin (Glargine / Detemir / Degludec): Provides steady 24-hour basal coverage with no pronounced peak, minimizing nocturnal hypoglycemia. Must NEVER be mixed in the same syringe with any other insulin.

Oral & Non-Insulin Hypoglycemic Agents

1. Biguanides (Metformin / Glucophage):
   • Mechanism: Decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. Does not stimulate insulin secretion (zero risk of hypoglycemia as monotherapy).
   • Critical Radiocontrast Safety Rule: Metformin must be withheld on the day of and for 48 hours following any procedure involving intravenous iodinated radiocontrast dye (e.g., CT with contrast, cardiac angiography). Radiocontrast can induce transient renal impairment, leading to metformin accumulation and fatal lactic acidosis. Renal function (BUN/creatinine) must be re-evaluated and confirmed normal before resuming.
2. Sulfonylureas (e.g., glipizide, glimepiride, glyburide): Stimulate pancreatic beta cells to secrete insulin. High risk of hypoglycemia and weight gain.
3. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (-gliflozin e.g., empagliflozin [Jardiance], dapagliflozin): Block renal glucose reabsorption in proximal tubules, promoting glucosuria. Adverse Effects: Mycotic genital infections, UTIs, hypotension, and euglycemic DKA.
4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (-glutide e.g., semaglutide [Ozempic, Wegovy], dulaglutide [Trulicity]): Subcutaneous or oral incretin mimetics that stimulate glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying. Adverse Effects: Nausea, vomiting, risk of pancreatitis, and thyroid C-cell tumors.

Thyroid Hormone Replacement: Levothyroxine

• Generic / Brand: Levothyroxine sodium (Synthroid, Levoxyl) (synthetic T4).
• Clinical Administration Rule: Must be taken once daily in the morning on an empty stomach with a full glass of water, at least 30 to 60 minutes before breakfast or any other medications.
• Interactions: Absorption is severely compromised by calcium supplements, iron (ferrous sulfate), antacids containing aluminum/magnesium, and sucralfate (separate by at least 4 hours).

---

3. Respiratory Pharmacology

+---------------------------------------------------------------------------------------------------+
|                                 RESPIRATORY MEDICATIONS CLASSIFICATION                            |
+---------------------------------------------------------------------------------------------------+
| SABA (Rescue)      | Albuterol (ProAir, Ventolin); rapid bronchodilation in acute bronchospasm.   |
| LABA (Maintenance) | Salmeterol (Serevent); long-term control; never used as monotherapy.        |
| Anticholinergics   | Ipratropium (Atrovent), Tiotropium (Spiriva); blocks cholinergic bronchocons.|
| Inhaled Steroids   | Fluticasone (Flovent), Budesonide (Pulmicort); rinse mouth to prevent thrush.|
| Leukotriene Blocker| Montelukast (Singulair); oral daily tablet for chronic asthma / allergies.   |
+---------------------------------------------------------------------------------------------------+

Bronchodilators

• Short-Acting Beta-2 Agonists (SABA - Rescue Inhalers): Albuterol (ProAir HFA, Ventolin HFA) and levalbuterol (Xopenex). Rapid onset ($<5\text{ minutes}$), duration 4–6 hours. First-line emergency drug for acute asthma exacerbations and bronchospasm. Side Effects: Tachycardia, palpitations, tremors, jitteriness, and hypokalemia.
• Long-Acting Beta-2 Agonists (LABA - Maintenance): Salmeterol (Serevent), formoterol. Onset 15–30 minutes, duration 12–24 hours. Used for chronic asthma and COPD control. Must never be used as a rescue inhaler during an acute attack, and in asthma, must always be combined with an inhaled corticosteroid.
• Inhaled Anticholinergics: Ipratropium bromide (Atrovent) (short-acting) and tiotropium (Spiriva) (long-acting). Inhibit acetylcholine-mediated bronchoconstriction and reduce excessive mucus secretions. Primary therapy for COPD.

Inhaled Corticosteroids (ICS) & Anti-Inflammatory Agents

• Inhaled Corticosteroids: Fluticasone propionate (Flovent), budesonide (Pulmicort), beclomethasone (QVAR).
  • Clinical Administration Rule: Patients must be instructed to rinse their mouth thoroughly with water and spit it out (do not swallow) immediately after using an inhaled steroid. This removes residual medication from the oropharyngeal mucosa, preventing oral candidiasis (thrush) and dysphonia (hoarseness).
• Leukotriene Receptor Antagonists (LTRAs): Montelukast (Singulair), zafirlukast. Oral daily tablet blocking leukotriene-mediated airway edema, smooth muscle constriction, and inflammation. Boxed warning for neuropsychiatric events (agitation, depression, suicidal thoughts).

---

4. Gastrointestinal & Antimicrobial Agents

Acid-Reducing Gastrointestinal Medications

• Proton Pump Inhibitors (PPIs):
  • Identifying Suffix: -prazole (e.g., omeprazole [Prilosec], pantoprazole [Protonix], esomeprazole [Nexium], lansoprazole).
  • Mechanism: Irreversibly inactivate the $\text{H}^+/\text{K}^+$ ATPase pump on gastric parietal cells, profoundly suppressing gastric acid secretion. Used for GERD, peptic ulcer disease, and Zollinger-Ellison syndrome. Administer 30–60 minutes before the first meal of the day.
  • Long-Term Risks: Hypomagnesemia, decreased calcium absorption leading to osteoporotic bone fractures, Vitamin B12 deficiency, and increased susceptibility to Clostridioides difficile colitis.
• Histamine-2 ($H_2$) Receptor Blockers:
  • Identifying Suffix: -tidine (e.g., famotidine [Pepcid], cimetidine [Tagamet]).
  • Mechanism: Competitively block $H_2$ receptors on parietal cells, reducing basal and nocturnal acid secretion.

Major Antimicrobial Classes & Critical Black Box Warnings

+---------------------------------------------------------------------------------------------------+
|                             ANTIMICROBIAL CLASSES & CRITICAL SAFETY ALERTS                        |
+---------------------------------------------------------------------------------------------------+
| Penicillins        | Amoxicillin, Penicillin VK; beta-lactam; cross-reactivity with cephalosporins.|
| Cephalosporins     | Cephalexin (Keflex), Ceftriaxone; beta-lactam (5-10% penicillin cross-react). |
| Macrolides         | Azithromycin (Z-Pak); CYP3A4 inhibitor; QT prolongation & dysrhythmias.      |
| Fluoroquinolones   | Ciprofloxacin, Levofloxacin; BLACK BOX: Tendon rupture & Achilles tendonitis.|
| Tetracyclines      | Doxycycline; photosensitivity; enamel hypoplasia/tooth stain in kids < 8.    |
| Sulfonamides       | TMP-SMX (Bactrim); sulfa allergy; Stevens-Johnson syndrome; nephrotoxicity.   |
| Antifungals        | Fluconazole (Diflucan); CYP450 inhibitor; hepatotoxicity; QT prolongation.   |
| Antivirals         | Acyclovir (Zovirax - HSV/VZV); Oseltamivir (Tamiflu - Influenza A/B).         |
+---------------------------------------------------------------------------------------------------+

1. Penicillins (e.g., amoxicillin, penicillin VK, ampicillin, amoxicillin/clavulanate [Augmentin]):
   • Beta-lactam antibiotics inhibiting bacterial cell wall peptidoglycan synthesis.
   • Safety Note: Most common cause of true drug-induced IgE anaphylaxis. Cross-reactivity of $5-10%$ exists with cephalosporins.
2. Cephalosporins (e.g., cephalexin [Keflex], cefdinir, ceftriaxone [Rocephin]):
   • Structured across five generations with expanding Gram-negative activity. Caution in patients with documented severe penicillin anaphylaxis.
3. Macrolides (e.g., azithromycin [Zithromax / Z-Pak], clarithromycin, erythromycin):
   • Inhibit bacterial 50S ribosomal protein synthesis. Highly useful for atypical community-acquired pneumonia and penicillin-allergic patients.
   • Adverse Effects: Gastrointestinal hypermotility, strong CYP3A4 inhibition (erythromycin/clarithromycin), and cardiac QT interval prolongation predisposing to Torsades de Pointes.
4. Fluoroquinolones (e.g., ciprofloxacin [Cipro], levofloxacin [Levaquin], moxifloxacin):
   • Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV.
   • FDA Black Box Warning: Associated with disabling and potentially irreversible adverse reactions including tendonitis and tendon rupture (most commonly the Achilles tendon), peripheral neuropathy, central nervous system toxicities, and exacerbation of myasthenia gravis. Instruct patients to discontinue immediately if tendon pain or swelling occurs.
5. Tetracyclines (e.g., doxycycline, minocycline, tetracycline):
   • Inhibit bacterial 30S ribosomal subunit. Used for Lyme disease, Rocky Mountain spotted fever, chlamydia, and acne.
   • Pediatric & Pregnancy Contraindication: Chelate with calcium in developing bone and enamel, causing permanent yellowish-brown tooth discoloration and enamel hypoplasia; strictly contraindicated in children under 8 years of age and pregnant women.
   • Other Effects: Severe photosensitivity (exaggerated sunburn); separate from antacids, dairy, and iron supplements by 2–3 hours.
6. Sulfonamides (e.g., trimethoprim-sulfamethoxazole [TMP-SMX / Bactrim, Septra]):
   • Inhibit bacterial folic acid synthesis. Used for uncomplicated UTIs, MRSA skin infections, and Pneumocystis jirovecii pneumonia.
   • Adverse Effects: Severe sulfa allergy hypersensitivity, crystalluria (must drink 2–3 liters of water daily to prevent renal tubular damage), photosensitivity, and potentially fatal Stevens-Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN).
7. Antifungals (e.g., fluconazole [Diflucan], terbinafine, nystatin):
   • Inhibit fungal ergosterol synthesis in cell membranes. Fluconazole is a potent CYP450 inhibitor; monitor liver function tests.
8. Antivirals:
   • Acyclovir (Zovirax) / Valacyclovir (Valtrex): Guanosine analog DNA polymerase inhibitors for Herpes Simplex (HSV-1, HSV-2) and Varicella Zoster (shingles).
   • Oseltamivir (Tamiflu): Neuraminidase inhibitor for acute Influenza A and B; must be initiated within 48 hours of symptom onset to significantly reduce illness duration.

Comprehensive Major Drug Classifications & Suffix Guide